Literature DB >> 18173815

Challenging the equipotency calculation for transdermal buprenorphine: four case studies.

R Likar1, B Krainer, R Sittl.   

Abstract

AIMS: Opioids produce analgesia via different pain pathways. The aim of these case studies was to address the issue of opioid rotation or switching, raising the important issue of conversion ratios between different compounds and routes of administration.
RESULTS: We present two cases of neuropathic pain and two cases of nociceptive pain with a significant neuropathic component, which were successfully treated with transdermal buprenorphine after the failure of other opioids.
CONCLUSION: In each case, effective pain relief was produced by a lower dose than the proposed equipotency ratio of 1:75 would indicate, suggesting that a ratio of 1:110 to 1:115 may be more appropriate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18173815     DOI: 10.1111/j.1742-1241.2007.01531.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  7 in total

1.  Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain.

Authors:  T Andresen; C Staahl; A Oksche; H Mansikka; L Arendt-Nielsen; A M Drewes
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 2.  Buprenorphine for treating cancer pain.

Authors:  Mia Schmidt-Hansen; Nathan Bromham; Mark Taubert; Stephanie Arnold; Jennifer S Hilgart
Journal:  Cochrane Database Syst Rev       Date:  2015-03-31

3.  Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.

Authors:  Sebastiano Mercadante; Alessandra Casuccio; Walter Tirelli; Antonello Giarratano
Journal:  Support Care Cancer       Date:  2008-12-23       Impact factor: 3.603

Review 4.  Pain management in patients with cancer: focus on opioid analgesics.

Authors:  Wojciech Leppert
Journal:  Curr Pain Headache Rep       Date:  2011-08

Review 5.  Toward a systematic approach to opioid rotation.

Authors:  Howard S Smith; John F Peppin
Journal:  J Pain Res       Date:  2014-10-17       Impact factor: 3.133

6.  A Comparative Study of Transdermal Buprenorphine and Oral Morphine in the Treatment of Chronic Pain of Malignant Origin.

Authors:  Kakali Choudhury; Partha Dasgupta; Nishana Paul; Krishnangshu Bhajna Choudhury; Bodhisatta Roy; Shampa Maity
Journal:  Indian J Palliat Care       Date:  2018 Oct-Dec

Review 7.  Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain.

Authors:  Tracy L Skaer
Journal:  J Pain Res       Date:  2014-08-19       Impact factor: 3.133

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.